Grifols (NASDAQ:GRFS) Issues Earnings Results

Grifols (NASDAQ:GRFS) released its earnings results on Monday. The biotechnology company reported $0.46 earnings per share for the quarter, beating the consensus estimate of $0.32 by $0.14, FiscalAI reports. Grifols had a net margin of 5.54% and a return on equity of 6.21%.

Grifols Stock Performance

Grifols stock traded up $0.38 during mid-day trading on Monday, hitting $8.47. 849,806 shares of the company’s stock traded hands, compared to its average volume of 641,149. The firm has a 50 day moving average price of $7.59 and a 200 day moving average price of $8.01. The company has a quick ratio of 0.81, a current ratio of 2.37 and a debt-to-equity ratio of 1.10. The company has a market cap of $5.77 billion, a PE ratio of 44.56, a price-to-earnings-growth ratio of 0.29 and a beta of 0.75. Grifols has a one year low of $6.96 and a one year high of $9.90.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Wall Street Zen lowered Grifols from a “buy” rating to a “hold” rating in a report on Saturday, October 10th. Zacks Research raised Grifols from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 7th. Weiss Ratings upgraded Grifols from a “sell (d)” rating to a “sell (d+)” rating in a research report on Monday, August 17th. Finally, JPMorgan Chase & Co. lowered their price objective on Grifols from $10.00 to $9.00 and set a “neutral” rating for the company in a research note on Monday, October 26th. Two equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Grifols currently has an average rating of “Reduce” and an average price target of $9.00.

Grifols Company Profile

Grifols SA is a global healthcare company headquartered in Barcelona, Spain, specializing in plasma-derived medicines and diagnostic technologies. The company develops, manufactures and markets therapies made from human plasma, including immunoglobulins, albumin and coagulation factors used to treat immune deficiencies, bleeding disorders and other chronic conditions.

Grifols operates a vertically integrated plasma business that includes plasma donation centers, collection and fractionation facilities, research and development, manufacturing and distribution.